Zacks currently has a $97 price objective on the stock, according to an analyst, “Stryker Corp. reported disappointing fourth quarter 2014 results.” However, the analyst noted, Stryker’s acquisition-driven strategy is expected to boost its growth profile by expanding its existing product offerings across all business segments.
Additionally, the expected FDA approval for MAKO total knee in 2015 is estimated to result in meaningful sales in the long term, according to the report.
More articles on devices:
K2M sets follow-on offering at $18.75 per share — 5 things to know
Implanet’s JAZZ technology receives intellectual patent protection in Europe
FTC makes second request for additional information on Wright Medical-Tornier merger — 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.